Summary
The product METH. ACET., manufactured by Driada Medical, underwent testing to determine its composition and dosage accuracy. The sample, identified by batch number 062435, was analyzed by Janoshik Analytical, a laboratory recognized for its pharmaceutical quality testing. The analysis confirmed the presence of methenolone acetate as the active ingredient, with a measured concentration of 26.10 mg per pill. This result reflects an accuracy of 104.4%, with a 4.4% variance above the labeled specification of 25 mg per pill, indicating slight overdosing.
The testing was commissioned and funded by Driada Medical and completed on 28 February 2022. The sample was retested twice to ensure reliability. Readers are encouraged to interpret these results critically, considering the manufacturer’s involvement in funding and submitting the sample. This report aims to support harm reduction and provide transparency to consumers.
Detailed Report
Product Overview
- Manufacturer: Driada Medical
- Product Name: METH. ACET.
- Active Ingredient: Methenolone Acetate
- Batch Number: 062435
- Expiration Date: Not provided
- Delivery Method: Oral
Sample Acquisition and Testing
- Task Number: #18690
- Testing Ordered: 21 February 2022
- Sample Received: 22 February 2022
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Driada Medical
- Analysis Paid For By: Driada Medical
Testing Results
- Specification: 25 mg per pill (as stated on the label)
- Measured Concentration: 26.10 mg per pill
- Accuracy: 104.4% (4.4% above the label claim)
Verification Details
- Verification URL: https://janoshik.com/tests/18690_DH6MT21KMHYK
- Originally Published: https://thinksteroids.com/community/posts/2920247/
Evaluation of Manufacturer-Funded Testing
This test was funded and submitted by Driada Medical, prompting careful scrutiny of potential biases. While manufacturer-funded testing can introduce factors like selective sample submission, the involvement of Janoshik Analytical, known for its transparent and reliable testing practices, provides confidence in the results. The additional retesting conducted strengthens the credibility of the findings. However, independent third-party testing remains a recommended method to validate these outcomes fully.
Conclusion
The analysis confirms that METH. ACET. is slightly overdosed, with a measured concentration of 26.10 mg per pill, exceeding the labeled specification of 25 mg per pill by 4.4%. This result indicates that the product meets and slightly surpasses its label claims. Such testing fosters transparency and supports informed decision-making in the use of anabolic steroid products.
Disclaimer
This report is published for educational and harm reduction purposes. Manufacturer-funded testing may involve inherent biases; however, it can still provide useful data when critically assessed alongside third-party or independent results. Readers are encouraged to use this information responsibly.
